Usefulness of Natriuretic Peptide Levels to Predict Mortality in Adults With Congenital Heart Disease

American Journal of Cardiology

Volumn 105, Issue 6, 2010, Pages 869-873

  Giannakoulas, Georgios ^a   Dimopoulos, Konstantinos ^a   Bolger, Aidan P ^b   Tay, Edgar Lik ^a   Inuzuka, Ryo ^a   Bedard, Elisabeth ^a   Davos, Constantinos ^a   Swan, Lorna ^a   Gatzoulis, Michael A ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CYANOTIC HEART DISEASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART VENTRICLE FUNCTION; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY;

EID: 77649182404     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.11.041     Document Type: Article

References (30)

1. Bolger A.P., Sharma R., Li W., Leenarts M., Kalra P.R., Kemp M., Coats A.J., Anker S.D., and Gatzoulis M.A. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106 (2002) 92-99
2. Hopkins W.E., Chen Z., Fukagawa N.K., Hall C., Knot H.J., and LeWinter M.M. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 109 (2004) 2872-2877
3. Book W.M., Hott B.J., and McConnell M. B-type natriuretic peptide levels in adults with congenital heart disease and right ventricular failure. Am J Cardiol 95 (2005) 545-546
4. Diller G.P., Dimopoulos K., Okonko D., Li W., Babu-Narayan S.V., Broberg C.S., Johansson B., Bouzas B., Mullen M.J., Poole-Wilson P.A., Francis D.P., and Gatzoulis M.A. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 112 (2005) 828-835
5. Dimopoulos K., Diller G.P., Koltsida E., Pijuan-Domenech A., apadopoulou S.A., Babu-Narayan S.V., Salukhe T.V., Piepoli M.F., Poole-Wilson P.A., Best N., Francis D.P., and Gatzoulis M.A. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation 117 (2008) 2320-2328
6. Bolger A.P., Coats A.J., and Gatzoulis M.A. Congenital heart disease: the original heart failure syndrome. Eur Heart J 24 (2003) 970-976
7. Koch A., Zink S., and Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 27 (2006) 861-866
8. Larsson D.A., Meurling C.J., Holmqvist F., Waktare J.E., and Thilen U.J. The diagnostic and prognostic value of brain natriuretic peptides in adults with a systemic morphologically right ventricle or Fontan-type circulation. Int J Cardiol 114 (2007) 345-351
9. Johns M.C., and Stephenson C. Amino-terminal pro-B-type natriuretic peptide testing in neonatal and pediatric patients. Am J Cardiol 101 (2008) 76-81
10. Law Y.M., Keller B.B., Feingold B.M., and Boyle G.J. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 95 (2005) 474-478
11. Tulevski I.I., Groenink M., van der Wall E.E., van Veldhuisen D.J., Boomsma F., Stoker J., Hirsch A., Lemkes J.S., and Mulder B.J. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart 86 (2001) 27-30
12. Kikuchi K., Nishioka K., Ueda T., Shiomi M., Takahashi Y., Sugawara A., Nakao K., Imura H., Mori C., and Mikawa H. Relationship between plasma atrial natriuretic polypeptide concentration and hemodynamic measurements in children with congenital heart diseases. J Pediatr 111 (1987) 335-342
13. Dimopoulos K, Diller GP, Petraco R, Koltsida E, Giannakoulas G, Tay EL, Best N, Piepoli MF, Francis DP, Poole-Wilson PA, Gatzoulis MA. Hyponatraemia: a strong predictor of mortality in adults with congenital heart disease. Eur Heart J Epub 2009 Nov 23.
14. Diller G.P., Dimopoulos K., Okonko D., Uebing A., Broberg C.S., Babu-Narayan S., Bayne S., Poole-Wilson P.A., Sutton R., Francis D.P., and Gatzoulis M.A. Heart rate response during exercise predicts survival in adults with congenital heart disease. J Am Coll Cardiol 48 (2006) 1250-1256
15. Berger R., Huelsman M., Strecker K., Bojic A., Moser P., Stanek B., and Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105 (2002) 2392-2397
16. Hansen D.E., Craig C.S., and Hondeghem L.M. Stretch-induced arrhythmias in the isolated canine ventricle. Evidence for the importance of mechanoelectrical feedback. Circulation 81 (1990) 1094-1105
17. Tomaselli G.F., Beuckelmann D.J., Calkins H.G., Berger R.D., Kessler P.D., Lawrence J.H., Kass D., Feldman A.M., and Marban E. Sudden cardiac death in heart failure: the role of abnormal repolarization. Circulation 90 (1994) 2534-2539
18. Babu-Narayan S.V., Kilner P.J., Li W., Moon J.C., Goktekin O., Davlouros P.A., Khan M., Ho S.Y., Pennell D.J., and Gatzoulis M.A. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcome. Circulation 113 (2006) 405-413
19. Masson S., and Latini R. Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure. Am J Cardiol 101 (2008) 56-60
20. Richards A.M., Doughty R., Nicholls M.G., MacMahon S., Sharpe N., Murphy J., Espiner E.A., Frampton C., Yandle T.G., and Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 37 (2001) 1781-1787
21. Gardner R.S., Ozalp F., Murday A.J., Robb S.D., and McDonagh T.A. N-terminal pro-brain natriuretic peptide: a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24 (2003) 1735-1743
22. Doust J.A., Pietrzak E., Dobson A., and Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330 (2005) 625-632
23. Koglin J., Pehlivanli S., Schwaiblmair M., Vogeser M., Cremer P., and von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38 (2001) 1934-1941
24. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., Wolf P.A., and Vasan R.S. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
25. Hamada Y., Tanaka N., Murata K., Takaki A., Wada Y., Oyama R., Liu J., Harada N., Okuda S., Hadano Y., and Matsuzaki M. Significance of predischarge BNP on one-year outcome in decompensated heart failure-comparative study with echo-Doppler indexes. J Card Fail 11 (2005) 43-49
26. Dimopoulos K., Giannakoulas G., Wort S.J., and Gatzoulis M.A. Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Curr Opin Cardiol 23 (2008) 545-554
27. Troughton R.W., and Richards A.M. Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurement. Am J Cardiol 101 (2008) 72-75
28. Pfisterer M., Buser P., Rickli H., Gutmann M., Erne P., Rickenbacher P., Vuillomenet A., Jeker U., Dubach P., Beer H., Yoon S.I., Suter T., Osterhues H.H., Schieber M.M., Hilti P., Schindler R., and Brunner-La Rocca H.P. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301 (2009) 383-392
29. Fruhwald F.M., Fahrleitner-Pammer A., Berger R., Leyva F., Freemantle N., Erdmann E., Gras D., Kappenberger L., Tavazzi L., Daubert J.C., and Cleland J.G. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 28 (2007) 1592-1597
30. Stanek B., Frey B., Hulsmann M., Berger R., Sturm B., Strametz-Juranek J., Bergler-Klein J., Moser P., Bojic A., Hartter E., and Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 436-442